Bivalirudin overdosage: Difference between revisions
Created page with "__NOTOC__ {{Bivalirudin}} {{CMG}} {{AE}}{{JH}} ==Title== <ref>{{Cite web | last = | first = | title = ANGIOMAX (BIVALIRUDIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTIO..." |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}}{{JH}} | {{CMG}} {{AE}}{{JH}} | ||
== | ==Overdosage== | ||
Cases of overdose of up to 10 times the recommended bolus or continuous infusion dose of Angiomax have been reported in clinical trials and in postmarketing reports. A number of the reported overdoses were due to failure to adjust the infusion dose of bivalirudin in persons with renal dysfunction including persons on hemodialysis [see Dosage and Administration (2.2)]. Bleeding, as well as deaths due to hemorrhage, have been observed in some reports of overdose. In cases of suspected overdosage, discontinue Angiomax immediately and monitor the patient closely for signs of bleeding. There is no antidote to Angiomax. Angiomax is hemodialyzable [see Clinical Pharmacology (12.3)].<ref>{{Cite web | last = | first = | title = ANGIOMAX (BIVALIRUDIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [THE MEDICINES COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=911cd48f-01ea-4dec-b30c-95e7e0ea9d2a | publisher = | date = | accessdate = 10 March 2014 }}</ref> | |||
<ref>{{Cite web | last = | first = | title = ANGIOMAX (BIVALIRUDIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [THE MEDICINES COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=911cd48f-01ea-4dec-b30c-95e7e0ea9d2a | publisher = | date = | accessdate = 10 March 2014 }}</ref> | |||
==References== | ==References== | ||
Revision as of 18:16, 10 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Overdosage
Cases of overdose of up to 10 times the recommended bolus or continuous infusion dose of Angiomax have been reported in clinical trials and in postmarketing reports. A number of the reported overdoses were due to failure to adjust the infusion dose of bivalirudin in persons with renal dysfunction including persons on hemodialysis [see Dosage and Administration (2.2)]. Bleeding, as well as deaths due to hemorrhage, have been observed in some reports of overdose. In cases of suspected overdosage, discontinue Angiomax immediately and monitor the patient closely for signs of bleeding. There is no antidote to Angiomax. Angiomax is hemodialyzable [see Clinical Pharmacology (12.3)].[1]
References
- ↑ "ANGIOMAX (BIVALIRUDIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [THE MEDICINES COMPANY]". Retrieved 10 March 2014.
Adapted from the FDA Package Insert.